Latest filing published 25 Sept 2021 for Glenmark Pharmaceuticals Limited, €58k.
Filing timeline
BuySaleGlenn Mario Saldanha: trading record in brief
Glenn Mario Saldanha (chief executive) discloses dealings in Glenmark Pharmaceuticals Limited to SEBI (PIT + SAST). Between 9 June 2021 and 24 September 2021, the trades on record add up to 4 filings.
On the market, this insider has only ever bought: 4 purchases, €191k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
In size, the median ticket on the buying side is €56k. Of 4 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.
The record was last updated on 25 September 2021 with an open-market purchase (€58k) in Glenmark Pharmaceuticals Limited. Filings reach the SEBI (PIT + SAST) feed a median of 1 day after the trade. Until a filing is published, the market cannot know about the trade. This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Glenn Mario Saldanha
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 9,800 shares@ ₹513.015230.4% of flowEquity SharesSEBI:32da8d7c912f1d4d9db504832ae09f596a698347Canonical exit: 23 Dec 2021 (T+90)
- 7,800 shares@ ₹640.000.0000% mcap42.4% of flowEquity SharesSEBI:fe9844636b32f99c393cfd6c43b8d98c8ab54355Canonical exit: 21 Sept 2021 (T+90)
- 2,800 shares@ ₹641.85610.0000% mcap15.2% of flowEquity SharesSEBI:8de2ea524f0611f5960938f5b20074c58d0281b6Canonical exit: 20 Sept 2021 (T+90)
- 7,870 shares@ ₹636.84160.0000% mcap42.4% of flowEquity SharesSEBI:cbe4bc773724e8e0f53f03e1d6508c57011868b5Canonical exit: 7 Sept 2021 (T+90)
4 of 4 declarations